Literature DB >> 22778866

ACS chemical neuroscience molecule spotlight on Qnexa.

Susan L Mercer1.   

Abstract

Qnexa (VI-0521) is an investigational fixed-dose combination drug of phentermine and topiramate currently in Phase III clinical trials for the treatment of obesity. Vivus, Inc. has demonstrated efficacy of their product and are currently addressing FDA safety concerns with the possibility of a New Drug Application (NDA) resubmission.

Entities:  

Keywords:  Qnexa; obesity; phentermine; topiramate; weight-loss

Mesh：

Substances：

Year:  2011        PMID： 22778866      PMCID： PMC3369742          DOI： 10.1021/cn200023v

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN： 1948-7193            Impact factor:   4.418


  3 in total

Review 1.  Appetite suppressants, cardiac valve disease and combination pharmacotherapy.

Authors:  Richard B Rothman; Michael H Baumann
Journal:  Am J Ther       Date:  2009 Jul-Aug       Impact factor: 2.688

Review 2.  An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action.

Authors:  R P Shank; J F Gardocki; A J Streeter; B E Maryanoff
Journal:  Epilepsia       Date:  2000       Impact factor: 5.864

3.  Prevalence and trends in obesity among US adults, 1999-2008.

Authors:  Katherine M Flegal; Margaret D Carroll; Cynthia L Ogden; Lester R Curtin
Journal:  JAMA       Date:  2010-01-13       Impact factor: 56.272
  3 in total
  1 in total

Review 1.  Phentermine and topiramate for the management of obesity: a review.

Authors:  Gina Cosentino; Ariane O Conrad; Gabriel I Uwaifo
Journal:  Drug Des Devel Ther       Date:  2011-04-05       Impact factor: 4.162
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.